Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma

Annals of Surgical Oncology

Volumn 23, Issue 9, 2016, Pages 2914-2919

  Grotz, Travis E ^a   Mansfield, Paul F ^a   Royal, Richard E ^a   Mann, Gary N ^a   Rafeeq, Safia ^a   Beaty, Karen A ^a   Overman, Michael J ^a   Fournier, Keith F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN;

ADENOCARCINOMA; ADULT; APPENDIX TUMOR; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DIAPHRAGM; DIAPHRAGM RESECTION; DISEASE FREE SURVIVAL; FEMALE; FULL THICKNESS DIAPHRAGM; HEMIDIAPHRAGM; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUCINOUS APPENDICEAL ADENOCARCINOMA; OPERATIVE BLOOD LOSS; OVERALL SURVIVAL; RETROSPECTIVE STUDY; THORACOABDOMINAL CHEMOPERFUSION; THORAX DISEASE; THORAX SURGERY; THORAX TUMOR; TUMOR RECURRENCE; COLLOID CARCINOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREVENTION AND CONTROL; REGIONAL PERFUSION; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA, MUCINOUS; APPENDICEAL NEOPLASMS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; DIAPHRAGM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84962271506     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-016-5209-0     Document Type: Article

References (13)

1. Wagner PL, et al. Extensive cytoreductive surgery for appendiceal carcinomatosis: morbidity, mortality, and survival. Ann Surg Oncol. 2013;20(4):1056–62.
2. Votanopoulos KI, et al. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015. 22(4):1274–9.
3. Chua TC, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56.
4. Elias D, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36(5):456-62.
5. Jimenez W, et al. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2014;21(13):4218–25.
6. Sugarbaker PH. Parietal peritonectomy. Ann Surg Oncol. 2012;19(4):1250.
7. Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg. 1994;219(2):109–11.
8. Sugarbaker PH, Fernandez-Trigo V, Shamsa F. Clinical determinants of treatment failure in patients with pseudomyxoma peritonei. Cancer Treat Res. 1996;81:121–32.
9. Zoetmulder FA, Sugarbaker PH. Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. Eur J Cancer. 1996;32A(10):1727–33.
10. Pestieau SR, Esquivel J, Sugarbaker PH. Pleural extension of mucinous tumor in patients with pseudomyxoma peritonei syndrome. Ann Surg Oncol. 2000;7(3):199–203.
11. Sugarbaker PH, Chang D, Stuart OA. Hyperthermic intraoperative thoracoabdominal chemotherapy. Gastroenterol Res Pract. 2012;2012:623417.
12. Ahmed S, et al. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014;21(13):4226–31.
13. Turaga K, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21(5):1501–5.